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Introduction
Male breast cancer (MBC) is infrequently observed in clinical 
practice and, therefore, unusual cases are not completely characterized 
and described. Male patients and physicians are less suspicious of such a 
disease and this may sometimes cause a diagnostic delay [1]. Only 48% 
of mucinous breast cancer is diagnosed at stage I/II of the disease so, in 
comparison with women, men tend to be diagnosed at a later stage of 
the disease. Therefore, its prognosis has not been significantly improved 
over the past 25 years [2]. Data from surveillance, epidemiology and end 
results (https://seer.cancer.gov) show that 93.7% of MBCs are ductal or 
unclassified carcinomas, and only 1.5% are lobular. Other tumor types 
include papillary (2.6%) and mucinous (1.8%) lesions [3]. Its incidence 
shows an increasing tendency and accounts for significant morbidity 
and mortality, showing a peak of incidence at around 60 years [4]. In 
addition to the better elucidation of the role of BRCA2, an increasing 
incidence of MBC has renewed interest in the pathogenesis and 
morphological features, clarifying specific differences between male 
and female breast cancer. Significant differences between male and 
female breast cancer have been reported. These regard the expression 
of a variety of biological parameters including hormone receptors such 
as estrogen and progesterone and c-erbB-2 receptors [5-7]. While 
male ductal intraepithelial neoplasia compared to similar lesions in 
females show a distinct histological profile, lesions are morphologically 
indistinguishable in invasive carcinomas [8,9]. There are 12 different 
types of breast cancer, of which infiltrating duct carcinoma is the most 
common. Mucinous carcinoma of the breast accounts for about 2% 
of breast carcinomas. Since male breast cancer is about 100 times less 
common than female breast cancer, mucinous carcinoma of the male 
breast is very rare [10]. It is probably due to such a low rate of breast 
cancer cases that men tend to be diagnosed at an older age than women 
and with a later stage of the disease [11]. Regarding the histological 
features, mucinous carcinomas are classified into pure and mixed 
types. The pure type shows >90% of a mucinous component and is also 
classified into hypo cellular and hyper cellular types. It is associated 
with lower rates of recurrence and indolent behavior. The mixed type 
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Abstract
Mucinous carcinoma of the male breast is an uncommon malignant breast neoplasm and its diagnoses remain 
difficult. It is probably due to such a low rate of breast cancer cases that men tend to be diagnosed at an older 
age than women and with a later stage of the disease. We describe a case of a 69-year-old male who displayed a 
palpable lump in his right axilla several years ago, showing signs of cutaneous adnexal mucinous adenocarcinoma 
after biopsy. After six years and several clinical examination and systemic investigation without results, the 
patient underwent to fine needle aspiration cytology and subsequently a biopsy of a mass with irregular margins 
in the retroareolar region of his right breast. The final diagnosis was of a mixed mucinous breast cancer with 
neuroendocrine differentiation. The tumor cells phenotype showed Synaptophisin (+), CEA (+/-), CK-20 (-), CK-7 
(+), TTF-1 (-), estrogen receptor (-), progesterone (-) and HER 2 (++). These results were unusual for a mucinous 
male breast carcinoma. In the presence of a lesion in the axillary area with no specific primary origin, breast cancer 
should never be ruled out, even in the absence of clinical evidence and with an immunohistochemical pattern not 
indicative of mammary origin.
behaves as aggressively as the isolated, invasive, solid component 
[12,13]. The Authors present a mucinous mixed type of the male breast, 
which was initially diagnosed as a mucinous carcinoma of the skin, 
reporting its clinical and pathological features.
Case Report
In February 2017, a 69-year-old male presented at Sant’Andrea 
Hospital, Rome, with an enlarged lump in the right breast and a palpable 
lesion in his right axilla. In December 2011, the patient had noticed 
thickening of the skin in the armpit area. During the examination, 
ultrasonography (US) revealed a hypoechoic, dishomogeneous area in 
the right axilla of 2 cm in diameter. Doppler US showed that the mass had 
internal vascularity. An x-ray of the thorax was negative. US confirmed 
the presence of a palpable lesion of the axilla but did not show any lesions 
in the breast. Other clinical examinations and systemic investigations 
including chest, abdominal and pelvis computed tomographies, and 
thyroid, breast and genitourinary tract ultrasound failed to detect any 
primary lesion elsewhere. BRCA analysis was negative and no family 
history of carcinomas was reported. The patient underwent incisional 
surgery and histopathology diagnosed a mucinous carcinoma. The 
immunohistochemical evaluation, performed according to the standard 
procedure, showed that tumor cells were positive for cytokeratin 20 
(Clone Ks20.8 Dako), weakly positive for CEA (Dako) and cytokeratin 
7 (clone OV-TL 12/30, Dako) but negative for ER (clone EP1, Dako), 
PgR (clone PgR636, Dako), TTF1 (clone 8G7G1/1 Dako) and. Ki67 was 
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30%. On the basis of these results, the hypothesis of a cutaneous adnexal 
mucinous adenocarcinoma was suggested. In 2013, ultrasonography 
(US) revealed two hypoechoic solid masses in the right axillary cavity. 
Fine-needle-aspiration cytology (FNAC) confirmed the neoplasia in 
the right axillary cavity and a histopathological examination revealed 
a mucin-producing adenocarcinoma in all the lymph nodes examined. 
As a result, the patient received adjuvant radiation therapy for 1 
month, followed by chemotherapy. In 2016, the clinical examination, 
US and PET/CT confirmed the presence of multiple metastatic lateral 
cervical, axillary and right mammary lymph node chains. An increased 
uptake was evident in the right mammary gland. The patient began 
consolidation chemotherapy with taxol from 02/2016 until 01/2017 
with a good response (partial response). Other clinical examinations 
and systemic investigations, including breast ultrasound were 
requested.
In 2017 US revealed a hypoechoic solid mass with irregular 
margins in the retroareolar region of the right breast and two lymph 
nodes with irregular margins in the right axillary cavity (Figure 1). 
A FNAC, supported by Rapid On-Site Evaluation (ROSE), of the 
breast lesion was performed. The cytological evaluation showed, in all 
smears, the presence of blood and mucus in the background, higher 
cellularity sometimes with nuclear atypia, overlapping, crowding 
and three-dimensional clusters (Figure 2) supporting the hypothesis 
of a primary breast tumor. In the same session, a core biopsy was 
performed. Histopathology revealed infiltrating ductal structures 
characterized by evident nuclear atypia, anisonucleosis, prominent 
nucleoli and mitotic activity in an extensive mucinous background. 
The immunohistochemical pattern showed that ER and PgR were both 
negative, p53 positive (24%), and c-erbB 2/neu very positive (continuous 
and strong membrane reactivity in more than 50% of the cells) and 
the MIB-1 (clone MIB-1, Dako) clone was 30-40%. Fluorescence in 
situ hybridization (FISH) assay for HER2 was amplified confirming 
the immunoreactivity (Figure 3). The lesion was also synaptophisin 
(Clone Synap, Dako) positive (Figure 4), confirming that the mucinous 
carcinoma is commonly associated with neurendocrine differentiation 
[4]. The histopathology diagnosis was a mixed mucinous and 
infiltrating carcinoma of the male breast. The patient received cycles 
of molecular target therapy and neoadjuvant chemotherapy. Then, in 
November 2017, the patient underwent a radical mastectomy.
Discussion
We presented a case of mucinous carcinoma initially diagnosed as 
a mucinous carcinoma of the skin. Seven years later, after excision at 
the primary site, it was classified as a mixed mucinous and infiltrating 
carcinoma of the breast. According to the literature, differential 
diagnosis between these tumors remains difficult. Three quarters 
of cases of mucinous carcinoma of the skin were found on the head 
while only 2% of mucinous carcinomas occurred on the chest [14]. 
Furthermore, mucinous carcinomas are classified into pure and mixed 
type, where the pure type shows the mucinous component in more than 
90% of the tumor; on the contrary, the mixed type shows mucinous 
and solid components formed by a ductal in situ, intraductal (IDC) 
or neuroendocrine differentiation carcinoma. The pure mucinous 
type is further sub-classified into hypocellular (A) and hypercellular 
Figure 1: Right breast ultrasonography revealed a hypoechoic solid mass 
with irregular margins approximately 1 cm in maximum size in the retro areolar 
region.
Figure 2: FNAC. Mucinous carcinoma showing pools of mucin and ductal 
cells. Nuclear atypia, overlapping and crowding is observe in cases of mixed 
mucinous and ductal carcinoma (Papanicolaou x200).
Figure 3: Fluorescence in situ hybridization (FISH) assay for HER2. This image 
shows the appearance of the dual-colored FISH assay (HER-2/neu DNA Probe 
Kit 17q 11.2-q12 Cromosoma 17 satellite alfa 17p11.1-q11.1, CEP17; Kreatech, 
Resnova, Italy), x1000 original magnification). Invasive tumor cell nuclei are 
highlighted by the blue fluorescent counter stain (4’,6-diamidino-2- phenylindole 
[DAPI]). Figure show HER2-amplified breast cancer with an increased number 
of HER2 gene signals (red signals) relative to CEP17 (green signals) resulting 
in a calculated HER2/CE17 ration of greater than 2.
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(B) types with a lower rate of recurrence and an indolent behavior; on 
the contrary, the mixed type proves to have more aggressive behavior 
[12,13,15]. At the first step of clinical investigation, our case presented 
a hypoechoic dishomogeneous area in the right axilla discovered by US. 
The lesion was treated by surgical excision and the histopathological 
evaluation showed a mixed type of mucinous carcinoma involving 
the skin. Clinical examinations and systemic investigations including 
chest, abdominal and pelvis computed tomographies, and thyroid, 
breast and genitourinary tract ultrasound failed to detect any primary 
lesion elsewhere. Analysis of various aspects of mammary carcinomas 
in men suggests some reasons for their worse behavior. Carcinomas 
of the male breast are usually superficial and beneath the nipple where 
the majority of mammary ducts are present. It is known that cancers 
in central locations of the breast in women have a worse prognosis 
than those in the more favorable areas such as the outer half of the 
breast. Also, the male breast lacks sufficient substance to encompass 
the tumor, so that the neoplasm has ready access to dermal lymphatics, 
pectoral fascia and subareolar lymphatic channels, metastatizing 
earlier in the axillary lymph nodes [16]. MBC with an unknown 
primary lesion, also defined as occult breast cancer, is a rare event and 
presents a “special kind” of breast cancer, of which the initial symptom 
is axillary lymphatic metastasis. Occult breast cancer is a type of 
cancer in which no lesions are found through physical or radiological 
examination such as mammography. It does not usually show any 
symptoms in the breast and it is often discovered from lymph node 
metastasis in the axillary area, supraclavicular or infraclavicular fossa 
[17]. In the case where only metastatic lesions are detected, without an 
original lesion, this is defined as carcinoma of unknown primary. In 
our case the first clinical manifestation was a skin mass of the armpit 
area. Even when the metastasis is detected in an axillary lymph node, it 
is difficult to be sure that occult is breast cancer. Although the axillary 
lymph node is known to be highly relevant to breast cancer, many 
other malignancies can metastatize to axillary lymph nodes, including 
lymphoma, melanoma, lung, thyroid and digestive tract carcinomas 
[18]. In the male patient studied, no breast mass was found at the 
first physical examination of the patient, not even a primary tumor 
was observed at US and PET/CT tests. After surgical removal of the 
skin lesion, the immunohistochemical tests showed that tumor cells 
were negative for ER and PgR. The literature reports that male breast 
cancers have high rates of hormone-receptor expression. Giordano 
et al detected that approximately 90% of male breast cancers express 
the estrogen receptor, and 81% express the progesterone receptor 
[11]. In contrast, the her2-neu proto-oncogene is less likely to be 
overexpressed in cancers of the male breast. In a large series of studies, 
human epidermal growth factor receptor-2 (HER-2) was observed in 
only one tumor out of 58 male breast cancers showing overexpression 
without amplification, compared with 26% of female breast cancer 
tumors showing overexpression and 27% manifesting amplification 
[3]. At present, there are no reports in the literature of MBC cases 
showing a mucinous carcinoma which is negative for ER/PgR and 
Her2neu amplified. This pattern is extremely uncommon in MBC. 
In fact, the literature reports that the immunoprofiles of mucinous 
carcinoma in males and females show fundamentally the same patterns 
[7,12]. Nevertheless, Ha et al reported a case of invasive mucinous 
breast carcinoma in a woman in which the lesion was estrogen and 
progesterone receptor negative and HER-2 positive [19]. Studies have 
revealed that there is a subset of patients with mucinous carcinoma 
showing mammographically occult neoplasms and/or multicentric 
multifocal disease. Some of these patients demonstrated metastases at 
presentation as well as ER/PR negative and HER-2 positive [20,21].
Conclusion
In these cases, immunohistochemistry was misleading. The 
presence of both negative hormonal receptors gave information 
that confused the diagnosis. Moreover, the histological pattern of a 
colloid carcinoma supported the hypothesis of a rare skin mucinous 
adenocarcinoma of the axilla, by ruling out other primary cancers. 
In conclusion, from our experience, in the presence of a lesion in the 
axillary area with no specific primary origin, breast cancer should 
never be ruled out, even in the absence of clinical evidence and with 
an immunohistochemical pattern not indicative of mammary origin. 
In this unusual case, it is probable that FNAC contributed significantly 
to the diagnosis and that the collaboration between the clinician and 
the pathologist led to a correct evaluation. The presence of the classic 
pattern of breast colloid carcinoma, found by breast FNAC, made the 
diagnosis evident. In this case, the cytopathology evaluations suggest 
a new hypothesis on the primary origin of the lesion, which was later 
supported by the histological examination.
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